[Surgery for small-cell lung cancer]

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology

Background:

• Small-cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma, frequently diagnosed at a metastatic stage.
• Surgical eligibility is limited to a small subset of patients with localized disease, often based on outdated evidence.
• Current treatment guidelines for SCLC surgery are primarily derived from older clinical trials and registry data.

Purpose of the Study:

• To evaluate the role and outcomes of surgical intervention in the multimodal management of small-cell lung cancer.
• To assess patient selection criteria and treatment sequences for operable SCLC.
• To determine the survival impact of surgery in early-stage SCLC.

Main Methods:

• Review of existing phase II/III trials and registry studies.
• Analysis of surgical procedures, including lobectomy and lymph node dissection.
• Evaluation of adjuvant and neoadjuvant chemotherapy regimens in conjunction with surgery.
• Assessment of patient selection factors such as age, performance status, and comorbidities.

Main Results:

• Surgery, typically lobectomy with lymph node removal, is feasible for select early-stage SCLC (pT1-2N0M0) within a multimodal approach.
• Adjuvant platinum-etoposide chemotherapy is recommended for resected stage I SCLC.
• Survival rates for early-stage SCLC treated with surgery and adjuvant chemotherapy range from 30% to 58% at 5 years.
• The role of surgery in locally advanced SCLC (T3-T4 or N2) is limited, though some registry data suggest potential survival benefits in N2 disease.

Conclusions:

• Surgery plays a vital role in achieving complete resection for early-stage SCLC, significantly improving survival.
• Treatment sequencing (neoadjuvant vs. adjuvant) remains a point of controversy due to clinical practice heterogeneity.
• Multidisciplinary evaluation is essential for optimizing treatment strategies in rare and heterogeneous SCLC cases.